[go: up one dir, main page]

IN2012DN00719A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00719A
IN2012DN00719A IN719DEN2012A IN2012DN00719A IN 2012DN00719 A IN2012DN00719 A IN 2012DN00719A IN 719DEN2012 A IN719DEN2012 A IN 719DEN2012A IN 2012DN00719 A IN2012DN00719 A IN 2012DN00719A
Authority
IN
India
Prior art keywords
compounds
disorders
compositions
useful
cftr
Prior art date
Application number
Inventor
Alan S Verkman
Lukmanee Tradtrantip
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IN2012DN00719A publication Critical patent/IN2012DN00719A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Provided herein are pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity. The compounds, and compositions comprising the compounds, described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, polycystic kidney disease. The compounds may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.
IN719DEN2012 2009-08-10 2010-08-10 IN2012DN00719A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23274109P 2009-08-10 2009-08-10
PCT/US2010/045052 WO2011019737A1 (en) 2009-08-10 2010-08-10 Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor

Publications (1)

Publication Number Publication Date
IN2012DN00719A true IN2012DN00719A (en) 2015-06-19

Family

ID=43586433

Family Applications (1)

Application Number Title Priority Date Filing Date
IN719DEN2012 IN2012DN00719A (en) 2009-08-10 2010-08-10

Country Status (6)

Country Link
US (1) US8609661B2 (en)
EP (1) EP2464354B1 (en)
CN (1) CN102695510A (en)
CA (1) CA2769847C (en)
IN (1) IN2012DN00719A (en)
WO (1) WO2011019737A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48842E1 (en) * 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9359381B2 (en) * 2012-12-19 2016-06-07 Novartis Ag Tricyclic compounds for inhibiting the CFTR channel
US9303035B2 (en) 2012-12-19 2016-04-05 Novartis Ag Substituted pyrazino[1′,2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
CN114948966B (en) * 2022-04-27 2023-06-20 南京鼓楼医院 Application of a small molecule inhibitor in the preparation of drugs for treating multiple sclerosis and sepsis
CN115998763A (en) * 2023-01-17 2023-04-25 暨南大学 Application of chloride ion and compound targeting chloride ion channel in regulation and control of iron death

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751969B1 (en) 1996-08-01 1998-12-04 Centre Nat Rech Scient CFTR CHANNEL ACTIVATING COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9626643D0 (en) * 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
FR2861304B1 (en) 2003-10-23 2008-07-18 Univ Grenoble 1 CFTR CHANNEL MODULATORS
WO2005094374A2 (en) 2004-03-30 2005-10-13 The Regents Of The University Of California Hydrazide-containing cftr inhibitor compounds and uses thereof
US7563793B2 (en) * 2004-12-20 2009-07-21 Wyeth Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents
BRPI0809498A2 (en) * 2007-04-02 2014-09-23 Inst Oneworld Health CFTR INHIBITOR COMPOUNDS AND THEIR USES
NZ586271A (en) 2007-12-13 2012-08-31 Vertex Pharma Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
MX2010010343A (en) 2008-03-25 2010-10-15 Univ California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator.
EP2288592A2 (en) 2008-04-04 2011-03-02 The Regents of the University of California Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor

Also Published As

Publication number Publication date
CA2769847C (en) 2019-01-08
WO2011019737A1 (en) 2011-02-17
EP2464354A4 (en) 2013-03-27
EP2464354A1 (en) 2012-06-20
CA2769847A1 (en) 2011-02-17
EP2464354B1 (en) 2015-04-01
CN102695510A (en) 2012-09-26
US8609661B2 (en) 2013-12-17
US20120208822A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
MX2010010343A (en) Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator.
IN2012DN00719A (en)
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
WO2008154251A3 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2008147797A3 (en) Ion channel modulators and methods of use
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
MY172151A (en) Certain chemical entities, compositions and methods
WO2008137633A3 (en) Methods of modulating cellular homeostatic pathways and cellular survival
WO2007064857A8 (en) Amphoteric liposome formulation
EP3632444A3 (en) Topical lfa-1 antagonists for use in localized treatment of immune related disorders
MX2012001156A (en) Trisubstituted boron-containing molecules.
WO2010059004A3 (en) Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
EA201071248A1 (en) DESIGNED PHTHALASINE ANTAGONISTS WAYS HEDGEHOG
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
IL190632A0 (en) Biphenyl derivatives and pharmaceutical compositions containing the same
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
IN2012DN02471A (en)
EP2765227A3 (en) Compositions and methods for identifying autism spectrum disorders
WO2008144223A3 (en) Triazolyl aminopyrimidine compounds
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2009158374A3 (en) Inhibitors of akt activity
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis